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Proteomic Evidence of Biological Aging in a Child with a
Compound Heterozygous ZMPSTE24Mutation
Angela K Lucas-Herald, Petra Zu¨rbig, Avril Mason, Esther Kinning, Catriona E Brown,
Bahareh Mansoorian, William Mullen, Syed Faisal Ahmed, and Christian Delles*
Background: Progeria-like syndromes oﬀer a unique insight into aging. Here
the case of a boy aﬀected with mandibuloacral dysplasia and compound
heterozygous mutations in ZMPSTE24 is presented.
Methods: Capillary electrophoresis-mass spectroscopy is used for proteome
analysis to analyze peptides previously found to be diﬀerentially regulated in
chronic kidney disease (273 peptides deﬁning the CKD273 classiﬁer),
coronary artery disease (238 peptides deﬁning the CAD238 classiﬁer), and
aging (116 peptides deﬁning the AGE116 classiﬁer).
Results: No evidence of renal disease is identiﬁed. Although the boy has no
overt cardiovascular disease other than a raised carotid intima media
thickness relative to his age, a proteomic classiﬁer for the diagnosis of
coronary artery disease is mildly raised. The biological age based on the
proteomic AGE116 classiﬁer is 24 years compared to the chronological ages of
5 and 10 years. In contrast, a control group of healthy children has a
signiﬁcantly lower (p < 0.0001) calculated mean age of 13.
Conclusion: Urinary proteomic analysis is eﬀective in conﬁrming advanced
biological age and to identify early evidence of renal or cardiovascular
damage. This case highlights the value of proteomic approaches in aging
research and may represent a method for non-invasive monitoring of the
eﬀects of early aging.
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Progeria-like syndromes are rare disor-
ders resulting in premature aging. With
an estimated prevalence of 1 in 20 mil-
lion people, the most common of these
syndromes is Hutchinson–Gilford proge-
ria syndrome (HGPS) (OMIM 176670),
caused by a de novo mutation in the
LMNA gene.[1] Patients with a similar
phenotype have reportedly suﬀered loss
of function mutations in ZMPSTE24
(zincmetalloproteinase STE24).[2] The as-
sociated phenotype is attributed to accu-
mulation of prelamin A, as ZMPESTE24
is a membrane protein which is crit-
ical in the posttranslational processing
of prelamin A to mature lamin A.[3] Af-
fected patients had characteristic facial
features (micrognathia, sparse thin hair,
small pinched nose, enlarged fontanelles
and delayed dentition) and postnatal
growth delay followed by the develop-
ment of lipodystrophy and renal and vas-
cular complications.[4] Animal models of
thesemutations demonstrate some of the
key hallmarks of aging including altered
chromatin organization, defective extra-
cellular matrix production, and cellular
senescence.[5] The interaction between genetic and environ-
mental factors in progeria-like syndromes can modify disease
processes, leading to diﬀerent phenotypes and disease progres-
sion despite similar genetic predisposition. In this context, anal-
ysis of protein biomarkers can provide a better description of the
disease process at a given point in time compared to analysis of
genetic factors that remain largely stable throughout life.
Urinary proteomics oﬀers the potential to screen large num-
bers of urinary biomarkers, which can then be used for non-
invasive early detection of disease.[6] Repeated blood sampling in
children can be challenging and distressing for children.[7] Al-
though there has been interest in whether it would be possible
to identify potential urinary biomarkers regarding the progres-
sion of disease in progeria-like syndromes, to date none have
been successfully identiﬁed. Prelamin A is located in the nuclear
lamina, making it challenging to identify in the urine. In 2006,
Adachi et al.[8] were able to identify only one fragment of Lamin
A/C in one sample with one speciﬁcmethod. As such, alternative
urinary biomarkers are still being sought.
In 2009, the low-molecular-weight urinary proteome of 324
healthy individuals between the ages of 2–73 years was analyzed,
identifying age related changes in the secretion of 325 urinary
peptides, the majority of which were associated with renal
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development before or during puberty and 49 peptides, which
were related to aging. Even in apparently healthy individuals,
there was evidence of markers of chronic age-related kidney dis-
ease, which may be pre-clinical. Further analysis demonstrated
that 13/49 peptides were most robustly associated with aging.[9]
More recently, urinary proteomes of 1227 healthy and
10 333 diseased individuals between 20–86 years of age were
investigated.[10] A total of 116 peptide biomarkers were iden-
tiﬁed that signiﬁcantly correlated with age in the healthy co-
hort. These peptides predominantly originated from collagen,
uromodulin, and ﬁbrinogen. While most ﬁbrillar and base-
ment membrane collagen fragments showed a decreased age-
related excretion, uromodulin, beta-2-microglobulin, and ﬁbrino-
gen fragments showed an increased urinary excretion. Using the
same capillary electrophoresis-mass spectroscopy (CE-MS) data
it is also possible to focus on peptides that are involved in speciﬁc
disease processes such as coronary artery disease and chronic
kidney disease.[11,12]
It is clear that urinary proteomics may provide useful insights
into vascular aging. Here we present the urinary proteomic pro-
ﬁle of a boy with a rare autosomal recessive progeria-like syn-
drome caused by a ZMPSTE24mutation.[13] He was born at term
with a birthweight of 3.71 kg (50th centile). There was no signif-
icant family history in his parents or his two older siblings. He
required pediatric review in his ﬁrst months because of failure
to thrive (0.4th centile). At 10 months, he was noted to have ab-
normal skull development. Bone biochemistry was normal but a
skull X-ray demonstrated widely patent fontanelles and wormian
bones over the occipital area. On further review at the age of
1.8 years, he had mid facial hypoplasia with sparse thin hair,
thin skin, prominent vasculature, normal clavicles, no plantar
arch, inward bowing of his legs, short stature (2nd centile, be-
low mid parental range) and delayed dental eruption. Skeletal
survey conﬁrmed osteopenic bones. Due to clinical suspicion of
mandibuloacral dysplasia, he had genetic testing which identi-
ﬁed one nonsense and one missense mutation in ZMPSTE24,
c.202C>T/c.743C>T predicting p.R68X/P248L.
The child is currently aged 11.9 years. He is growing along
the 2nd centile and on no regular medications, other than
multivitamin drops containing 400 units ergocalciferol. He has
osteonecrosis of his left hip that has not required any surgical
intervention. His bone density is low (total body density −2.2;
lumbar spine −1.3). His renal function and echocardiogram are
normal and his blood pressure has remained on the 50th centile
for height and age. Carotid intima media thickness (CIMT)
measurements of the common carotid artery at the age of 10.7
years, taken as previously described[14] using the Siemens Acu-
son Sequoia 512 (California, USA) demonstrated that his CIMT
was 0.47mm, which is on the 95th centile for age.[15] Pulse wave
velocity measured using the SphygmoCor system (AtCorMedical
Ltd, Sydney, Australia) was on the 25th centile for height and
age.[16]
Spot urine samples of the case were collected at two time
points in 2012 (age 5 years) and 2017 (age 10 years). Further-
more, spot urine samples of two healthy controls at the age of
5 years and two healthy controls at the age of 10 years were used.
The preparation of the urine samples, CE-MS analysis, and data
processing were performed as described previously in detail[12]
and although the samples were from diﬀerent time points, no
degradation would be expected as demonstrated previously by
Zu¨rbig et al.[17] Mass spectral ion signals representing identi-
cal molecules at diﬀerent charge states were deconvoluted into
single masses using the MosaiquesVisu software.[18] To achieve
high mass accuracy, deconvoluted mass signals were calibrated
based on a Fourier-transform ion cyclotron resonancemass spec-
trometer (Bruker Daltonics Apex Qe instrument equipped with
a 12-tesla magnet and an Apollo II ion source) with accurate
masses (mass deviation of 1 ppm) as described.[12,19] In parallel,
CE-migration timewas normalized by local regression and signal
intensities using internal standards.[20] All analyses passed qual-
ity control. Classiﬁcation of the urine samples based on a com-
parison of the levels of biomarkers detected in the urine of the
individual patient to the levels of those biomarkers identiﬁed us-
ing SVM-based classiﬁer, the MosaDiagnostics software (version
1.4.0), and the previously deﬁned classiﬁers for chronic kidney
disease and coronary artery disease were used.[21] Furthermore,
with the previously identiﬁed 116 aging peptide biomarkers,[10]
an SVM-based classiﬁer (AGE116) was generated based on ran-
domly selected 45 young (age: 20–29 years) and 45 old (age: >60
years) healthy individuals of the original cohort. The correlation
between the classiﬁcation scores of this classiﬁer and the age of
the subjects resulted in a coeﬃcient of rho= 0.77 (95% CI: 0.67–
0.84; p< 0.0001). The classiﬁer was further validated with the rest
of the original cohort and resulted in a correlation of rho = 0.64
(p < 0.0001). A p-value of 0.1 was considered statistically signiﬁ-
cant due to the low number of samples.
Individual peptide data from the CE-MS runs are available in
Table S1, Supporting Information. We focused on the analysis of
peptides that have been previously found in other studies to be
diﬀerentially regulated in coronary artery disease (238 peptides
deﬁning the CAD238 classiﬁer)[22] and chronic kidney disease
(273 peptides deﬁning the CKD273 classiﬁer)[12] and were found
to be associated with aging (116 peptides deﬁning the AGE116
classiﬁer). Classiﬁer scores are presented in Table 1. The CKD273
classiﬁer was within the normal range at both time points, pro-
viding no evidence of subclinical renal disease in this patient.
The CAD238 classiﬁer for coronary artery disease was above the
threshold of −0.140 in 2012 and in the normal range but close
to the threshold in 2017. We also constructed a regression model
for the AGE116 classiﬁer based on previously published data[10]
so that we were able to transform the score into an estimated
biological age. In 2012, at the chronological age of 5 years, the
biological age based on AGE116 classiﬁer was 23.8 years, and it
remained 24.1 years in 2017 when the chronological age was 10
years.
To compare the estimated biological age which was calculated
with theAGE116 classiﬁer, we used a control group of two healthy
children at the age of 5 and two at the age of 10, extracted from the
Human Urinary Database.[21] The estimated biological age of the
younger control group was 12.5 years and for the older control
group was 13.1 years which was (at both ages) signiﬁcantly (p <
0.0001) lower than the estimated biological age of the case subject
(see Table 1)
Furthermore, we compared expression of individual peptides
that deﬁne the AGE116 classiﬁer of the case samples with the
mean expression of these peptides in the above control group
(Figure 1). We found nine peptides which were signiﬁcantly dif-
ferent in the mean expression of the case samples compared to
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Table 1. Proteomic classiﬁer scores. Cut-oﬀ values for CAD238 and CKD237 for diagnosis of coronary artery disease and chronic kidney disease are
−0.140 and 0.343, respectively, with higher values representing presence and lower values absence of disease.
2012 2012 2012 2017 2017 2017 Age 5 Age 5 Age 5 Age 10 Age 10 Age 10
Sample 1 Sample 2 Mean Sample 1 Sample 2 Mean Control 1 Control 2 Mean Control 3 Control 4 Mean
CAD238 0.283 −0.198 0.043 −0.018 −0.161 −0.090 −0.270 −0.225 −0.248 −0.537 −0.289 −0.413
CKD273 −0.412 −0.363 −0.388 −0.481 −0.319 −0.400 −1.276 −0.442 −0.859 −0.849 −0.871 −0.860
AGE116 −1.104 −0.960 −1.032 −0.988 −1.047 −1.018 −1.634 −1.541 −1.588 −1.527 −1.589 −1.558
Predicted age 22.4 25.3 23.8 24.7 23.5 24.1 11.6 13.5 12.5 13.8 12.5 13.1
Figure 1. Mean amplitude of signiﬁcant peptides.
controls (Table S2, Supporting Information). Six of these showed
a higher expression in the urine of healthy controls than in the
case samples; ﬁve derived from collagen alpha-1 type I and III. A
decrease in the mean expression of collagen peptides may be the
result of the accumulation of ECM during aging secondary to
reduced ECM degradation.[10] Although this number of collagen-
derived peptides may appear low, in the study by Nkuipou-
Kenfack et al., only 55 collagen derived peptides were identiﬁed
from a sample of 1227 individuals,[10] suggesting that our output
is reasonable given the relatively smaller number of samples. Fur-
thermore, we identiﬁed three peptides, which are fragments of
ﬁbrinogen alpha and beta chain and of uromodulin with a higher
mean expression in the control than in case samples. The urinary
excretion of these peptides showed a positive correlation with
age.[23]
Although these proteomic markers are not currently validated
as routine clinical parameters, there is accumulating evidence
of their diagnostic potential.[24] Given that our data demonstrate
that urinary peptide analysis by CE-MS does correlate eﬀectively
with clinical phenotype, this could be a non-invasive alternative
to plasma protein analysis. The proteomic age classiﬁer we have
generated demonstrates a clear discrepancy between estimated
biological age and chronological age. However, the estimated bi-
ological age identiﬁed as 24 years may be less than expected in
light of the boy’s aged musculoskeletal phenotype. This age clas-
siﬁer provides an estimate of overall age and is not organ speciﬁc.
More advancedmusculoskeletal age can therefore be outweighed
by other clinical parameters such as normal renal function with
no discrepancy between chronological and estimated biological
age.
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One potential limitation of this work is that the classiﬁers used
have been calculated using adult data. The urinary proteome
changes signiﬁcantly during puberty[9]; therefore, it is diﬃcult
to ﬁnd peptides from a pediatric population which correlate with
age. The classiﬁers we have used are therefore themost appropri-
ate currently available to us. Our group has previously used the
CKD273 classiﬁer in children with chronic kidney disease and
have found it to be accurate, with a diﬀerent reference range to
the adult population. Our group has not previously usedmarkers
associated with CAD in children.
To conclude, we have demonstrated that urinary proteomic
analysis can be used to conﬁrm advanced estimated biological
age in a boy with a progeria-like syndrome. Our data correlate
with the patient’s physical characteristics and although in our
boy there are no immediate consequences of this ﬁnding, with
future research, proteomics could represent a method for non-
invasive monitoring of similarly aﬀected patients for clinical de-
terioration. The progeria-like syndromes oﬀer a unique insight
into normal and pathological aging processes that aﬀect multi-
ple organ systems at the same time that have individually been
subject to previous and ongoing proteomic studies. Our case,
therefore, highlights the value of proteomic approaches in ag-
ing research and provides insights into molecular features of
multimorbidity.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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